Anti-BRAF35 Antibody

Mutations of the human BRCA2 gene confer susceptibility to breast cancer. A structural DNA binding component has been identified and is designated as BRCA2-Associated Factor 35 (BRAF35). There is a close association of the BRAF35/BRCA2 complex with condensed chromatin coincident with histone H3 phosphorylation. Experimental evidence suggests a role for the BRCA2/BRAF35 complex in the modulation of cell cycle progression.